Skip to main content
Eva Barragan on Muck Rack

Eva Barragan

Los Angeles
As seen in: Nature, Wiley Online Library, Red Bull, MDPI, Flaunt, Golden Gate Xpress, Happening in DTLA
what's your story?
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Eva

Contact Eva, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Impact of molecular profiling in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: a study by the PETHEMA group

|
By Rafael Colmenares, Eva Barragan, Rebeca Rodríguez-Veiga, Joaquin Sanchez-Garcia, Mar Tormo, Teresa Bernal, Pilar Martínez-Sánchez, Eduardo Rodríguez-Arbolí, Cristina Gil, Elena Soria-Saldise, Josefina Serrano, María García-Fortes, Cristina Fernandez Bilbao, José Luis Lopez-Lorenzo, María José Larráyoz, Esperanza Lavilla-Rubira, Lorenzo Algarra, Carmen Chillón, Carmen Couto, Víctor M. Noriega, Manuel Muñoz Barrios, Ana Cabello, Jorge Labrador, Maria Mateos Verified, Manuel Pérez-Encinas, María García-Pérez, Juan Bergua, Gonzalo Carreno-Tarragona, Joaquín Martínez-López, Rosa Ayala, Pau Montesinos, Laura Torres-Miñana, Esther Pérez-Santaolalla, María Carmen García-Garay, Melissa Torres-Ochando, Raimundo García-Boyero, Ágata Almela, Marta Callejas, Soledad Casado, Amaia Balerdi, María Luz Amigo, Lissette Costilla
| Nature Verified
Abstract Acute myeloid leukemia (AML) is a heterogeneous malignancy with a poor prognosis. Genetic and molecular profiling help guide treatment decisions, including the use of allogeneic hematopoietic stem cell transplantation (allo-HSCT), to reduce relapse risk. This study evaluated the impact of individual and co-mutational genetic profiles in AML patients in first complete remission after receiving allo-HSCT using data from the PETHEMA registry.
Open in Who Shared Issue with article?

CEBPA‐bZIP Mutations in AML Patients Treated With Non‐Intensive Therapy: A Study by the Spanish PETHEMA Registry

|
By Josefina Serrano, Eva Barragan, Rosa Ayala, María José Calasanz
| Wiley Online Library Verified
Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement For original data, please contact Dr. Pau Montesinos, montesinos_pau@gva.es. Peer Review The peer review history for this article is available at link https://www.webofscience.com/api/gateway/wos/peer-review/10.1002/hon.70162.
Open in Who Shared Issue with article?

A heterozygous CEBPA mutation disrupting the bZIP domain in a RUNX1 and SRSF2 mutational background causes MDS disease progression - Nature Communications

|
By Peter Keane, Syed A. Mian, Carl C. Ward, George Murphy, Arwa F. Flemban, Saeed M Kabrah, Eirini P. Papapetrou, Ildem Akerman, Manoj Raghavan, Eva Barragan, Dominique Bonnet, Constanze Bonifer, Khadidja Habel
| Nature Verified
Abstract Myelodysplastic syndrome disease (MDS) is caused by the successive acquisition of mutations and thus displays a variable risk for progression to AML. Mutations in CEBPA are commonly associated with a high risk of disease progression, but whether they are causative for AML development is unclear. To analyse the molecular basis of disease progression we generated MDS patient-derived induced pluripotent stem cells from a low risk male patient harbouring RUNX1/SRSF2 mutations.
Open in Who Shared Issue with article?
See all 19 articles